Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 31, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.

Mohamad Abou Chakra1, Igor Duquesne2, Michael A O'Donnell1

  • 1Department of Urology, University of Iowa Health Care, Iowa City, IA 52242, USA.

Frontiers in Bioscience (Landmark Edition)
|May 30, 2026
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Reply by Authors.

The Journal of urology·2026
Same author

Clinical spectrum, outcome and impact of nephrectomy in critically-ill adult patients with emphysematous pyelonephritis: the PYELEMPHY observational retrospective multicenter Study.

Annals of intensive care·2026
Same author

Exploring the efficacy of the storage organizational model in the urology suite at a single institution.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2026
Same author

Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.

BJU international·2026
Same author

Advancing bladder cancer detection: commentary on a urinary DNA methylation diagnostic assay.

Translational andrology and urology·2026
Same journal

Conditional Immortalization of Human Cardiac Fibroblasts for Pro-Fibrotic and Anti-Fibrotic Drug Screening.

Frontiers in bioscience (Landmark edition)·2026
Same journal

NF-κB Involvement in Glaucoma-Associated Neuroinflammation: Focus on Glial Cells.

Frontiers in bioscience (Landmark edition)·2026
Same journal

Revealing the Molecular Network of Pattern-Triggered Immunity (PTI) Signal Transduction.

Frontiers in bioscience (Landmark edition)·2026
Same journal

β-Ecdysterone Attenuates Ang II-Induced Senescence in Human Aortic Smooth Muscle Cells via Autophagy Activation and ROS Suppression Through AKT/mTOR Pathway Inhibition.

Frontiers in bioscience (Landmark edition)·2026
Same journal

Exploration of the Role of M2 Macrophages in Hepatocellular Carcinoma: Insights into Disulfidptosis and Cellular Interactions.

Frontiers in bioscience (Landmark edition)·2026
Same journal

The Gut-Bone Axis: Molecular Mechanisms and Therapeutic Perspectives in Skeletal Homeostasis.

Frontiers in bioscience (Landmark edition)·2026
See all related articles

Bacillus Calmette-Guérin (BCG) therapy for non-muscle-invasive bladder cancer (NMIBC) often fails due to immune evasion within the tumor microenvironment. Novel intravesical immunotherapies show promise but require combination strategies targeting these escape mechanisms.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Non-muscle-invasive bladder cancer (NMIBC) represents a significant portion of bladder cancer diagnoses.
  • Intravesical Bacillus Calmette-Guérin (BCG) is the standard treatment for intermediate- and high-risk NMIBC, but treatment failure occurs in up to 40% of patients.
  • Radical cystectomy, while effective, involves substantial morbidity, necessitating bladder-sparing alternatives.

Purpose of the Study:

  • To review the immunologic mechanisms underlying BCG therapy efficacy and failure in NMIBC.
  • To examine multifactorial immune evasion mechanisms within the tumor microenvironment (TME) that contribute to BCG resistance.
  • To highlight emerging intravesical immunotherapies for BCG-unresponsive NMIBC.

Main Methods:

Keywords:
BCG unresponsive diseaseBacillus Calmette-Guérinimmune evasionimmunotherapynon muscle invasive bladder cancertumor microenvironmenturinary bladder neoplasms

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Experiment Videos

Last Updated: May 31, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

  • Review of immunologic mechanisms of BCG therapy and immune evasion in NMIBC.
  • Identification and discussion of ten principal immune suppression mechanisms in the TME.
  • Summary of emerging intravesical immunotherapies and their platforms.

    • Main Results:

    • Ten key immune suppression mechanisms in the TME hinder BCG efficacy, including myeloid-derived suppressor cells, regulatory T cells, PD-1/PD-L1, NKG2A/HLA-E, CD6-ALCAM signaling, T cell exhaustion, and cancer-associated fibroblasts.
    • These mechanisms disrupt antigen presentation, suppress immune responses, and promote tumor progression.
    • Emerging immunotherapies like nadofaragene firadenovec, nogapendekin alfa inbakicept-pmln, cretostimogene grenadenorepvec, and detalimogene voraplasmid show promise but lack comparative data.

    Conclusions:

    • Understanding TME immune dynamics is crucial for developing effective bladder-sparing alternatives to BCG.
    • Combination strategies targeting multiple immune escape mechanisms are needed for BCG-unresponsive NMIBC.
    • Further research with comparative studies and predictive biomarkers is essential for optimizing novel immunotherapy selection.